Skip to main content

Case studies

Discover how we turn challenges into triumphs.

Our case studies highlight real-world examples of how we’ve leveraged our expertise to drive success for our clients. Each case study provides an in-depth look at the unique problems our clients faced, the tailored strategies we developed, and the outcomes we achieved together.

Value demonstration and health economic modelling for AI cardiac CT interpretation tool
Validation of disease burden and health economic model assumptions through expert elicitation
Targeted literature review on NICE’s preferred method for incorporating caregiver decrements in an appraisal
Systematic literature review and indirect treatment comparison to expand a treatment population
Synthesis of new estimates of comparative efficacy for a treatment for an ophthalmology condition
Support for an innovative respiratory drug throughout the NICE ILAP process
Strategic modelling in oncology
Securing EU4+UK reimbursement in diagnostics
Revenue-generated early access programmes in rare diseases
Reimbursement support in Ireland including gathering clinician opinion and leading negotiations with HSE Commercial Pharmaceutical Unit team
Recommendations of potential positioning for an asset in chronic myeloid leukaemia based on EU4+UK payer insights
Rapid deployment of an HTA development team
Phase 3 study design assessment and recommendations
Multi-indication oncology HTA management
Meta-analysis of clinical trial data informing a NICE submission
Market model and entry evaluation for a MedTech device in Europe
Managing a product range in a crowded immunology market
Leading the pricing and reimbursement process for an oncology product in European markets
Launch sequence to manage appetite for reimbursement and maximise pricing for a gene therapy
Innovative health economic modelling for a haematology drug
Indirect treatment comparison feasibility study in a rare inherited liver condition
Incorporating KOL and payer insights into the HTA process for an immunology drug
In-depth critical review and black box testing of a third-party economic model in nephrology
Identifying economically justifiable pricing for key global markets
HTA submission support in the UK and Ireland for a nephrology product
Gaining early patient access and generative revenue through a holistic early access strategy
EUnetHTA Joint Scientific Advice
Developing and updating a GVD and PVP: Joined up thinking
Developing an early cost-effectiveness model to identify economic drivers, pricing potential, and evidence gaps
Developing a launch strategy and internal review process for a client working in oncology
Demonstrating logistical challenges in a real world setting to identify areas for treatment improvement
AMCP dossier for formulary submission for a gene therapy
Access and HE launch support for a hypoxic blood device